Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
otrezetil + omeprazole
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Otrezetil (CP-945,598) is a potent and selective cannabinoid receptor 1 (CB1) antagonist developed by Pfizer, primarily investigated for the treatment of obesity and smoking cessation. Omeprazole is a well-established proton pump inhibitor (PPI) used to reduce gastric acid secretion. The combination of otrezetil and omeprazole was specifically evaluated in Phase 1 clinical pharmacology studies to assess potential drug-drug interactions (DDI). These trials aimed to determine if the elevation of gastric pH or the inhibition of CYP2C19 by omeprazole would significantly alter the pharmacokinetic profile of otrezetil. Development of otrezetil was ultimately discontinued by Pfizer following the withdrawal of other CB1 antagonists from the market due to psychiatric safety concerns.
- Other names
- CP-945,598 + omeprazole
02
Targets
CNR1 (Cannabinoid receptor 1)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on otrezetil + omeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on otrezetil + omeprazole.